FDA Inspection 663187 — Glaxosmithkline
The FDA completed an inspection of Glaxosmithkline on May 14, 2010 in Uxbridge. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- May 14, 2010
- Fiscal Year
- 2010
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Uxbridge (United Kingdom)
Additional details
Sponsor, Contract Research Organization